Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III extension study of efficacy, safety and tolerability of Chronocort in the treatment of congenital adrenal hyperplasia (CAH)

X
Trial Profile

A Phase III extension study of efficacy, safety and tolerability of Chronocort in the treatment of congenital adrenal hyperplasia (CAH)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydrocortisone (Primary)
  • Indications Congenital adrenal hyperplasia
  • Focus Adverse reactions; Registrational
  • Sponsors Diurnal
  • Most Recent Events

    • 14 May 2024 According to a Neurocrine Biosciences media release, data from the study were presented at the European Congress of Endocrinology 2024 meeting in Stockholm.
    • 14 May 2024 Results presented in the Neurocrine Biosciences Media Release
    • 18 Jun 2023 Results (n=71) of a post-hoc analysis assessing total glucocorticoid daily dose and 9am 17-hydroxyprogesterone levels in MRHC treated patients after 24 months presented at the 105th Annual Meeting of the Endocrine Society
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top